Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online October 17, 2007
Diabetes 57:255-258, 2008
DOI: 10.2337/db07-0999
© 2008 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0999v1
57/1/255    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shield, J. P.H.
Right arrow Articles by Ellard, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shield, J. P.H.
Right arrow Articles by Ellard, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Mosaic Paternal Uniparental Isodisomy and an ABCC8 Gene Mutation in a Patient With Permanent Neonatal Diabetes and Hemihypertrophy

Julian P.H. Shield1, Sarah E. Flanagan2, Deborah J. Mackay3,4, Lorna W. Harries2, Peter Proks5, Christophe Girard5, Frances M. Ashcroft5, I. Karen Temple3,4, and Sian Ellard2

1 Department of Endocrinology and Diabetes, Bristol Royal Hospital for Children and University of Bristol, Bristol, U.K
2 Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, U.K
3 Wessex Regional Genetics Laboratory and Clinical Genetics Service, Salisbury District Hospital, Salisbury, Wiltshire, U.K
4 Division of Human Genetics, University of Southampton, Southampton, U.K
5 University Laboratory of Physiology, Oxford, U.K

Address correspondence and reprint requests to Professor Sian Ellard, Peninsula Medical School, Barrack Road, Exeter, EX2 5DW, U.K. E-mail: sian.ellard{at}rdeft.nhs.uk

Key Words: BWS, Beckwith-Wiedemann syndrome • KATP channel, ATP-sensitive K+ channel • UPD, uniparental isodisomy


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 DISCUSSION
 REFERENCES
 
OBJECTIVE— Activating mutations in the KCNJ11 and ABCC8 genes encoding the Kir6.2 and SUR1 subunits of the pancreatic ATP-sensitive K+ channel are the most common cause of permanent neonatal diabetes. In contrast to KCNJ11, where only dominant heterozygous mutations have been identified, recessively acting ABCC8 mutations have recently been found in some patients with neonatal diabetes. These genes are co-located on chromosome 11p15.1, centromeric to the imprinted Beckwith-Wiedemann syndrome (BWS) locus at 11p15.5. We investigated a male with hemihypertrophy, a condition classically associated with neonatal hyperinsulinemia and hypoglycemia, who developed neonatal diabetes at age 5 weeks.

RESEARCH DESIGN AND METHODS— The KCNJ11 and ABCC8 genes and microsatellite markers on chromosome 11 were analyzed in DNA samples from the patient and his parents.

RESULTS— A paternally inherited activating mutation (N72S) in the ABCC8 gene was identified in the proband. The mutation was present at 70% in the patient's leukocytes and 50% in buccal cells. Microsatellite analysis demonstrated mosaic segmental paternal uniparental isodisomy (UPD) of 11pter-11p14 in the proband that encompassed the ABCC8 gene and the BWS locus.

CONCLUSIONS— We report a patient with neonatal diabetes, hemihypertrophy, and relatively high birth weight resulting from telomeric segmental paternal UPD of chromosome 11, which unmasks a recessively acting gain-of-function mutation in the ABCC8 gene and causes deregulation of imprinted genes at the BWS locus on 11p15.5.

Neonatal diabetes is a rare condition of hyperglycemia usually presenting during infancy or soon thereafter (1). Etiologies other than autoimmunity are far more prevalent if diabetes is diagnosed before the age of 6 months (2). Recent developments have highlighted the importance of ion channel mutations ("channelopathies") in the etiology of both permanent and transient forms of this condition (3–5). The pancreatic β-cell ATP-sensitive K+ channel (KATP channel) is composed of four inward rectifying K+ channel (Kir6.2) subunits, encoded by the gene KCNJ11, and four sulfonylurea receptor (SUR1) subunits encoded by ABCC8. Its role is to control insulin release in response to glucose metabolism within the β-cell, through alterations in adenine nucleotide availability and binding (6). Inactivating mutations in either KCNJ11 or ABCC8 cause persistent hyperinsulinemic hypoglycemia of infancy (7,8). Recently, Gloyn and colleagues described activating mutations in KCNJ11 as the cause of many cases of permanent (9) and a few cases of transient (10) neonatal diabetes; this has been confirmed in a large follow-up series (5,11). The mutant KATP channels display reduced sensitivity to ATP-induced closure, thus preventing both membrane depolarization and insulin release in response to glucose. Clinically, it has been demonstrated that many, but not all, children affected by mutations in KCNJ11 can replace insulin therapy with high-dose oral sulfonylureas, usually glyburide (known in the U.K. as glibenclamide) (12).

Activating mutations in the ABCC8 gene have also been linked to neonatal diabetes (3–5,13–15). Mutations may result in either a transient or permanent form of the disease. Like the KCNJ11 mutations, they cause the KATP channel to remain open even when ATP is elevated by glucose metabolism. Clinically, neonatal diabetes due to ABCC8 mutations can also be abrogated through the therapeutic use of sulfonylureas (3,4).

Hemihypertrophy describes asymmetric overgrowth of part or half of the body. It may be isolated or part of the Beckwith-Wiedemann syndrome (BWS), a condition characterized by macroglossia, abdominal wall defects, neonatal hyperinsulinemia, and increased risk of embryonal tumors (16). Both isolated hemihypertrophy and BWS can be caused by mosaic paternal uniparental isodisomy of chromosome 11p15 (17,18).


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
DISCUSSION
 REFERENCES
 
A male child weighing 3.87 kg at 40 weeks gestation (75th percentile) was born to nonconsanguineous, Somali parents. There had been two previous uneventful pregnancies. The proband was discharged home on the day of birth but returned to hospital aged 36 days, failing to thrive, severely dehydrated, and acidotic (pH 6.99 [normal range {NR} 7.3–7.4]). The initial blood glucose measured was 50 mmol/l with a bicarbonate of 5 mmol/l (NR 21–34) and urinary ketones of >160 mg/dl. A diagnosis of neonatal diabetes was made, and subsequent to resuscitation the child was stabilized on twice-daily subcutaneous insulin. Both parents had normal fasting glucose levels (father 5.2 mmol/l, age 36 years; mother 4.6 mmol/l, age 31 years) and no prior history of diabetes.

The child had left hemihypertrophy (Fig. 1) but no macroglossia, anterior abdominal wall defects, ear creases, or peri-auricular pits as seen in BWS. Echocardiography of the heart revealed branch pulmonary artery stenosis but no cardiomegaly, while serial abdominal ultrasounds identified increasing left renal hypertrophy compared with a normal right kidney.


Figure 1
View larger version (87K):
[in this window]
[in a new window]

  		FIG. 1. Photograph of proband showing hemihypertrophy of left leg.

 
Investigations.
The young age of the patient at presentation suggested a diagnosis of neonatal diabetes. Blood was collected for DNA analysis of chromosome 6 anomalies causing transient neonatal diabetes (19) and for KCNJ11 mutation analysis (which at this time was the only channelopathy described as causing permanent neonatal diabetes). These tests were both normal. GAD, insulin, and islet cell autoantibodies were all negative. The child's karyotype was normal: 46 XY. However, microsatellite analysis of chromosome 11 revealed the child to be mosaic for paternal uniparental isodisomy (UPD) of 11pter-11p14 (Table 1 and Fig. 2A). As neonatal diabetes is not characteristic of either BWS or isolated hemihypertrophy, this prompted a review of potential candidate genes for diabetes that were encompassed within this region of UPD. The SUR1 gene (ABCC8), which lies within this region, was a logical candidate, as it coassembles with Kir6.2 (KCNJ11) to form the KATP channel, and activating mutations in KCNJ11 are known to cause neonatal diabetes (9–11).


View this table:
[in this window]
[in a new window]

  		TABLE 1 Microsatellite analysis of proband revealing mosaic segmental paternal UPD of chromosome 11

 

Figure 2
View larger version (14K):
[in this window]
[in a new window]

  		FIG. 2. Results of microsatellite analysis and ABCC8 sequencing. A: Analysis of microsatellite D11S1318 (2.29 Mb from pter, i.e., within the BWS locus). x-axis indicates product size (base pairs); y-axis indicates product quantity (arbitrary units). Note the smaller peak for the maternal allele in the proband's blood sample compared with the buccal sample. B: Pedigree showing mutation status and sequencing electropherograms. The solid symbol indicates the affected proband, and the father is shown as an unaffected carrier of the mutation (dot within an unfilled symbol). The mutated base is indicated by an arrow on the electropherograms.

 
The ABCC8 gene was sequenced as described previously (14). The father was identified as being heterozygous for a missense mutation, N72S (c.215A>G), while the proband's leukocyte DNA showed mosaicism for the N72S mutation (Fig. 2B). The N72S mutation was not found in 250 normal chromosomes, and the affected residue was conserved across species. Quantification by real-time PCR (TaqMan assay) demonstrated that the N72S mutation was present at ~70% in leukocyte DNA and 50% in buccal cells. Briefly, genomic DNA from leukocytes and buccal cells was amplified using a mutation-specific TaqMan approach. Genomic DNA from the father, who is heterozygous for the N72S mutation, was used in serial dilution to produce standard curves to determine linear range and accuracy of quantification (primer and probe sequences are available on request). Reactions contained 5 µl TaqMan Fast Universal PCR Mastermix without Amperase, 0.5 µl Assays-by-Design (Applied Biosystems, Warrington, U.K.) probe and primer mix (corresponding to 36 µl of each primer and 8 µl of each probe), 2.5 µl water, and 2 µl DNA at a concentration of 100 ng/µl. Amplification conditions consisted of a single cycle of 95°C for 20 s followed by 40 cycles of 95°C for 1 s and 60°C for 20 s. The relative level of mutant transcript relative to wild-type transcript was determined by the {Delta}{Delta}CT method (20). Each test was carried out in triplicate.

Functional studies in Xenopus oocytes (methods in 9,10) demonstrated that the N72S mutation results in a reduced sensitivity to inhibition by MgATP. Half-maximal block of homozygous N72S channels was produced by 23 ± 1 µmol/l ATP (n = 10) compared with 15 ± 1 µmol/l (n = 6) for wild-type channels. Two-electrode voltage-clamp studies showed a concomitant small increase in the whole-cell KATP channel resting current (14) (Fig. 3). Homozygous N72S channels were substantially blocked by the sulfonylurea tolbutamide in vitro (Fig. 3).


Figure 3
View larger version (20K):
[in this window]
[in a new window]

  		FIG. 3. Resting whole-cell KATP channel currents are slightly larger for homomeric N72S mutant channels and are blocked by sulfonylureas. Mean steady-state whole-cell KATP channel currents for wild-type (WT), homomeric (hom) N72S, and heterozygous (het) N72S channels, as indicated evoked by a voltage step from –10 to –30 mV before ({square}, resting condition), after application of the metabolic inhibitor 3 mmol/l azide (blk12), and in the presence of 3 mmol/l azide plus 0.5 mmol/l tolbutamide ({blacksquare}). The number of oocytes is given below the bars.

 
Identification of an ABCC8 mutation, together with the patient's relatively poor control on twice-daily insulin (GHb 8.3% NR 4.0–6.0%), the known efficacy of sulfonylureas in neonatal diabetes caused by KATP channel mutations (21), and the tolbutamide block of mutant N72S channels observed in functional studies, prompted a trial of the sulfonylurea glyburide. Over a 2-week period, under intensive monitoring in the hospital, regular subcutaneous insulin was withdrawn and glyburide gradually increased from a starting dose of 0.1 mg · kg–1 · day–1 to a maximum dose of 1 mg · kg–1 · day–1.

The therapeutic trial was terminated at 2 weeks due to the complete absence of a clinical response, with high blood glucose levels (up to 40 mmol/l) requiring the repeated administration of short-acting insulin to improve glycemia and prevent metabolic decompensation. The C-peptide level before initiating glyburide was <94 pmol/l and remained at <94 pmol/l on 1 mg · kg–1 · day–1 glyburide. The child is now over 18 months of age and is treated with a basal bolus insulin regimen of four injections daily (~1 unit · kg–1 · day–1) to maintain growth and health (recent A1C 6.6%). Although his neurological development at this stage seems normal, he remains under regular surveillance both for neurocognitive development and for increased tumor risk.


   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 DISCUSSION
REFERENCES
 
Uniparental isodisomy is a rare abnormality that provides insights into the genetic basis of human disease. Its identification in two cases of transient neonatal diabetes (22) led to identification of imprinting anomalies associated with the transient form of this condition. UPD can also unmask genetic disorders with an autosomal recessive pattern of inheritance (23). In this case, the child's hemihypertrophy and relatively high birth weight (75th centile) did not fit with a diagnosis of permanent neonatal diabetes as, if anything, these features would be expected to co-segregate with hypoglycemia secondary to hyperinsulinemia (as seen in BWS). Since UPD can unmask recessive disorders, SUR1 (ABCC8) was an obvious candidate, due to its position within the disomic region of interest, its importance in insulin secretion, and the fact that focal adenomatous hyperplasia of islet cells with congenital hyperinsulinemia has been described in which loss of maternal 11p15 is associated with homozygosity of an ABCC8 mutation inherited from a heterozygous father (24).

Recent studies have identified activating mutations in ABCC8 as causing both transient and permanent neonatal diabetes (3–5). Several cases of permanent neonatal diabetes responded to glyburide at doses ranging from 0.22 to 0.59 mg · kg–1 · day–1 (3), including one child with a dominant ABCC8 mutation (15) and at least four children with recessively inherited ABCC8 mutations (A.T. Hattersley, S.E.F., S.E., unpublished observations). Unfortunately, the child reported here was unresponsive to glyburide at a dose of as much as 1 mg · kg–1 · day–1. The complete absence of any clinical response in our infant prompted our withdrawal of glyburide after a 2-week trial, although a further trial when the child is older may be warranted given the in vitro response. The lack of a therapeutic response to sulfonyureas in our patient is puzzling, as the mutant N72S channels were blocked by tolbutamide in in vitro studies. It is possible that other imprinted genes involved in the paternal UPD might confer a reduced response.

In conclusion, we report a patient with UPD of chromosome 11 who presented with neonatal diabetes as opposed to the classical phenotype of hypoglycemia due to hyperinsulinemia. Paternal UPD of chromosome 11pter-11p14, encompassing the KATP channel genes and the BWS locus, unmasked a recessively acting gain-of-function ABCC8 gene mutation, thus causing diabetes in addition to features of BWS. As has previously been described, the heterozygous father has no history of glucose intolerance or evidence of diabetes in adult life, as this is a recessively acting mutation (14). The level of mosaicism for the N72S mutation varied between leukocytes (~70% mutation) and buccal cells (~50% mutation). As the child is alive and well, the mutation load within the pancreas remains unknown. Given the evidence that children with UPD11 can have highly variable levels of mosaicism in different organs, we hypothesize that the pancreas must exhibit a high level of paternal UPD cells to present with this phenotype, the somatic recombination causing the paternal UPD occurring very early during embryogenesis (25).

We have recently identified nine other patients with recessively inherited ABCC8 mutations causing neonatal diabetes (14).


   ACKNOWLEDGMENTS
 
We acknowledge funding from the Sir Graham Wilkins studentship to S.E.F. and support from the Research & Development Directorate at the Royal Devon & Exeter NHS Foundation Trust to S.E.


   FOOTNOTES
 
Published ahead of print at http://diabetes.diabetesjournals.org on 17 October 2007. DOI: 10.2337/db07-0999.

J.P.H.S. and S.E.F. contributed equally to this work.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication July 19, 2007 and accepted in revised form October 11, 2007


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 DISCUSSION
 REFERENCES
 

  1. Polak M, Shield J: Neonatal and very-early-onset diabetes mellitus. Semin Neonatol 9:59–65, 2004[Medline]
  2. Edghill EL, Dix RJ, Flanagan SE, Bingley PJ, Hattersley AT, Ellard S, Gillespie KM: HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 55:1895–1898, 2006[Abstract/Free Full Text]
  3. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 355:456–466, 2006[Abstract/Free Full Text]
  4. Vaxillaire M, Dechaume A, Busiah K, Cave H, Pereira S, Scharfmann R, de Nanclares GP, Castano L, Froguel P, Polak M: New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 56:1737–1741, 2007[Abstract/Free Full Text]
  5. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D, Shield JP, Temple K, Ellard S, Hattersley AT: Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56:1930–1937, 2007[Abstract/Free Full Text]
  6. Slingerland AS, Hattersley AT: Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med 37:186–195, 2005[Medline]
  7. Thomas PM, Cote GJ, Wohilk N, Haddad B, Mathew PM, Rabel W, Aquilar-Bryan L, Gagel RF, Byran J: Mutations in the sulphonylurea receptor and familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268:426–429, 1995[Abstract/Free Full Text]
  8. Thomas PM, Yuyang Y, Lightner E: Mutation of the pancreatic islet inward rectifier, Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 5:1809–1812, 1996[Abstract/Free Full Text]
  9. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838–1849, 2004[Abstract/Free Full Text]
  10. Gloyn AL, Reimann F, Girard C, Edghill EL, Proks P, Pearson ER, Temple IK, Mackay DJ, Shield JP, Freedenberg D, Noyes K, Ellard S, Ashcroft FM, Gribble FM, Hattersley AT: Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet 14:925–934, 2005[Abstract/Free Full Text]
  11. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT: Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49:1190–1197, 2006[Medline]
  12. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Sovik O, Polak M, Hattersley AT: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477, 2006[Abstract/Free Full Text]
  13. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, Colclough K, Hattersley AT, Ashcroft FM, Ellard S: A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet 15:1793–1800, 2006[Abstract/Free Full Text]
  14. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, Edghill EL, Mackay DJ, Proks P, Shimomura K, Haberland H, Carson DJ, Shield JP, Hattersley AT, Ashcroft FM: Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 81:375–382, 2007[Medline]
  15. Masia R, De Leon DD, MacMullen C, McKnight H, Stanley CA, Nichols CG: A mutation in the TMD0–L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM). Diabetes 56:1357–1362, 2007[Abstract/Free Full Text]
  16. Engstrom W, Lindham S, Schofield P: Wiedemann-Beckwith syndrome. Eur J Pediatr 147:450–457, 1988[Medline]
  17. West PM, Love DR, Stapleton PM, Winship IM: Paternal uniparental disomy in monozygotic twins discordant for hemihypertrophy. J Med Genet 40:223–226, 2003[Free Full Text]
  18. Henry I, Puech A, Riesewijk A, Ahnine L, Mannens M, Beldjord C, Bitoun P, Tournade MF, Landrieu P, Junien C: Somatic mosaicism for partial paternal isodisomy in Wiedemann-Beckwith syndrome: a post-fertilization event. Eur J Hum Genet 1:19–29, 1993[Medline]
  19. Temple IK, Shield JP: Transient neonatal diabetes, a disorder of imprinting. J Med Genet 39:872–875, 2002[Abstract/Free Full Text]
  20. Harries LW, Ellard S, Jones RW, Hattersley AT, Bingham C: Abnormal splicing of hepatocyte nuclear factor-1 beta in the renal cysts and diabetes syndrome. Diabetologia 47:937–942, 2004[Medline]
  21. Lebovitz H, Melander A: Sulfonylureas: basic aspects and clinical uses. In International Textbook of Diabetes Mellitus. 2nd ed. Alberti KGMM, Zimmet P, DeFronzo RA, Eds. London, Wiley, 1997, p.817–840
  22. Temple IK, James RS, Crolla JA, Sitch FL, Jacobs PA, Howell WM, Betts P, Baum JD, Shield J: An imprinted gene(s) for diabetes? Nat Genet 9:110–112, 1995[Medline]
  23. Zlotogora J: Parents of children with autosomal recessive diseases are not always carriers of the respective mutant alleles. Hum Genet 114:521–526, 2004[Medline]
  24. Verkarre V, Fournet JC, de Lonlay P, Gross-Morand MS, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 102:1286–1291, 1998[Medline]
  25. Itoh N, Becroft DM, Reeve AE, Morison IM: Proportion of cells with paternal 11p15 uniparental disomy correlates with organ enlargement in Wiedemann-beckwith syndrome. Am J Med Genet 92:111–116, 2000[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
K. Hussain, S. E. Flanagan, V. V. Smith, M. Ashworth, M. Day, A. Pierro, and S. Ellard
An ABCC8 Gene Mutation and Mosaic Uniparental Isodisomy Resulting in Atypical Diffuse Congenital Hyperinsulinism
Diabetes, January 1, 2008; 57(1): 259 - 263.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0999v1
57/1/255    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shield, J. P.H.
Right arrow Articles by Ellard, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shield, J. P.H.
Right arrow Articles by Ellard, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum